blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2626432

EP2626432 - Method for the diagnosis of myeloid neoplasias and solid tumors and diagnostic kits [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.09.2015
Database last updated on 01.10.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Universitätsklinikum Freiburg
Hugstetter Strasse 49
79106 Freiburg / DE
[2013/33]
Inventor(s)01 / Pahl, Heike
Spargelweg 32
79112 Freiburg / DE
02 / Jutzi, Jonas
Schwabentorring 6
79089 Freiburg / DE
 [2013/33]
Representative(s)Keller, Günter, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
[2014/46]
Former [2013/33]Keller, Günter, et al
Lederer & Keller Patentanwälte Unsöldstrasse 2
80538 München / DE
Application number, filing date12154405.008.02.2012
[2013/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2626432
Date:14.08.2013
Language:EN
[2013/33]
Type: B1 Patent specification 
No.:EP2626432
Date:12.11.2014
Language:EN
[2014/46]
Search report(s)(Supplementary) European search report - dispatched on:EP03.07.2012
ClassificationIPC:C12Q1/68
[2013/33]
CPC:
C12Q1/6886 (EP,US); C12Q2600/156 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/33]
TitleGerman:Verfahren zur Diagnose von myeloiden Neoplasien und feste Tumore und Diagnosekits[2013/33]
English:Method for the diagnosis of myeloid neoplasias and solid tumors and diagnostic kits[2013/33]
French:Procédé pour le diagnostic de néoplasies myéloïdes et de tumeurs solides et trousses de diagnostic[2013/33]
Examination procedure30.01.2014Examination requested  [2014/11]
13.02.2014Amendment by applicant (claims and/or description)
21.05.2014Communication of intention to grant the patent
30.09.2014Fee for grant paid
30.09.2014Fee for publishing/printing paid
30.09.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.05.2014
Opposition(s)13.08.2015No opposition filed within time limit [2015/43]
Fees paidRenewal fee
27.02.2014Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.02.2012
AL12.11.2014
BG12.11.2014
CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
IT12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
MK12.11.2014
MT12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SI12.11.2014
SK12.11.2014
SM12.11.2014
TR12.11.2014
IE08.02.2015
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
[2018/46]
Former [2018/31]HU08.02.2012
BG12.11.2014
CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
IT12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
MK12.11.2014
MT12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SI12.11.2014
SK12.11.2014
SM12.11.2014
TR12.11.2014
IE08.02.2015
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2017/39]HU08.02.2012
BG12.11.2014
CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
IT12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
MT12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SI12.11.2014
SK12.11.2014
SM12.11.2014
TR12.11.2014
IE08.02.2015
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2017/03]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
IT12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
MT12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SI12.11.2014
SK12.11.2014
IE08.02.2015
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2016/12]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
IT12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SI12.11.2014
SK12.11.2014
IE08.02.2015
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2016/07]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
IT12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SK12.11.2014
IE08.02.2015
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2016/03]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
IT12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SK12.11.2014
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/46]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
LT12.11.2014
LV12.11.2014
MC12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SK12.11.2014
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/44]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
LT12.11.2014
LV12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SK12.11.2014
LU08.02.2015
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/37]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
LT12.11.2014
LV12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
SK12.11.2014
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/36]CY12.11.2014
CZ12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
LT12.11.2014
LV12.11.2014
PL12.11.2014
RO12.11.2014
RS12.11.2014
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/35]CY12.11.2014
EE12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
LT12.11.2014
LV12.11.2014
PL12.11.2014
RS12.11.2014
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/26]CY12.11.2014
ES12.11.2014
FI12.11.2014
HR12.11.2014
LT12.11.2014
LV12.11.2014
PL12.11.2014
RS12.11.2014
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/24]ES12.11.2014
FI12.11.2014
HR12.11.2014
LT12.11.2014
LV12.11.2014
PL12.11.2014
RS12.11.2014
NO12.02.2015
GR13.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/23]ES12.11.2014
FI12.11.2014
LT12.11.2014
NO12.02.2015
IS12.03.2015
PT12.03.2015
Former [2015/22]LT12.11.2014
NO12.02.2015
PT12.03.2015
Former [2015/21]LT12.11.2014
NO12.02.2015
Former [2015/20]LT12.11.2014
Documents cited:Search[A]WO2008060090  (UNIV NAT CHONNAM IND FOUND [KR], et al) [A] 1-9 * the whole document *;
 [XA]US2002197611  (CHAGOVETZ ALEXANDER MICHAEL [US]) [X] 10,11 * the whole document * * page 6, column r * [A] 1-9,12;
 [X]US2005118625  (MOUNTS WILLIAM M [US]) [X] 10,11 * sequence 294246 *;
 [X]US2009053752  (BLACKMAN BRETT R [US], et al) [X] 10,11 * sequence 15 *;
 [X]WO2005085474  (CLONTECH LAB INC [US], et al) [X] 10,11 * sequence 15 *
 [XA]  - KAUFMANN KAI B ET AL, "A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, (20120116), vol. 209, no. 1, doi:10.1084/JEM.20110540, ISSN 0022-1007, pages 35 - 50, XP008152985 [X] 10,11 * the whole document * * page 47 * [A] 1-9,12

DOI:   http://dx.doi.org/10.1084/jem.20110540
 [XDA]  - PHILIPP S. GOERTTLER ET AL, "Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2", BRITISH JOURNAL OF HAEMATOLOGY, (20050401), vol. 129, no. 1, doi:10.1111/j.1365-2141.2005.05416.x, ISSN 0007-1048, pages 138 - 150, XP055030489 [XD] 10,11 * the whole document * * page 138 * [A] 1-9,12

DOI:   http://dx.doi.org/10.1111/j.1365-2141.2005.05416.x
 [XDA]  - W. WANG ET AL, "AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2", BLOOD, (20100715), vol. 116, no. 2, doi:10.1182/blood-2009-11-254664, ISSN 0006-4971, pages 254 - 266, XP055030492 [XD] 10,11 * the whole document * * page 255 * [A] 1-9,12

DOI:   http://dx.doi.org/10.1182/blood-2009-11-254664
 [A]  - R SHIVDASANI, "Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoeitin/MGDF in megakaryocyte development", CELL, (19950601), vol. 81, no. 5, doi:10.1016/0092-8674(95)90531-6, ISSN 0092-8674, pages 695 - 704, XP055030639 [A] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.1016/0092-8674(95)90531-6
 [A]  - T. BEAN, "Multiple regions of p45 NF-E2 are required for beta-globin gene expression in erythroid cells", NUCLEIC ACIDS RESEARCH, (19970615), vol. 25, no. 12, doi:10.1093/nar/25.12.2509, pages 2509 - 2515, XP055030727 [A] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.1093/nar/25.12.2509
 [XDA]  - TSUTOMU TOKI ET AL, "Functional characterization of the two alternative promoters of human p45 NF-E2 gene", EXPERIMENTAL HEMATOLOGY, (20001001), vol. 28, no. 10, doi:10.1016/S0301-472X(00)00523-3, ISSN 0301-472X, pages 1113 - 1119, XP055030495 [XD] 10,11 * the whole document * * page 1114, column r - page 1115, column l * [A] 1-9,12

DOI:   http://dx.doi.org/10.1016/S0301-472X(00)00523-3
ExaminationUS2011104680
by applicant   - IGARASHI, NATURE, (1994), vol. 367, pages 568 - 572
    - GOERTTLER ET AL., BRITISH JOURNAL OF HEMATOLOGY, (2005), vol. 129, pages 138 - 150
    - WANG ET AL., BLOOD, (2010), pages 254 - 266
    - TOKI ET AL., EXP. HEMATOL., (2000), vol. 28, pages 1113 - 1119
    - TEMERINAC ET AL., BLOOD, (2000), vol. 95, pages 2569 - 2576
    - STEIMLE ET AL., ANN.HEMATHOL., (2007), vol. 86, pages 239 - 244
    - SCHREIBER ET AL., NUCLEIC ACID RES., (1989), vol. 17, page 6419
    - MIGNOTTE ET AL., PNAS, (1989), vol. 86, pages 6548 - 52
    - ROELZ ET AL., EXP. HEMATOL., (2010), vol. 38, pages 792 - 7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.